tirzepatide and hormone replacement therapy New research from a Mayo Clinic–led study suggests that postmenopausal women using menopause may experience greater weight loss when treated with tirzepatide, a GLP-1–based medication for overweight obesity. In Hormone therapy supercharges weight loss

Give it a few days and see how you feel

Karakasis P et al

[1] [2] These results represent a degree of weight reduction not previously observed with any pharmacological agent in a trial of this duration, though Phase 3 data are required before firm conclusions can be drawn

Muscle pain specifically was not broken out as a separate category, making direct comparison difficult

I tell people online they could try this, after consulting a doctor, because this is really helpful.Supply outlookInjectables are expected to be available in India from next year, when Eli Lilly plans to launch Mounjaro, Reuters reported

Unfortunately, there have not been any large controlled studies on the topic of how GLP-1 medications like semaglutide and tirzepatide affect menstrual cycles in women who do not have PCOS, so we just do not have enough data to make a solid determination of the effects of GLP-1s on menstruation